Adverse Events and Safety of SARS-CoV-2 Vaccines: What's New and What's Next.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 35550878.
- Also identified by DOI 10.1016/j.jaip.2022.04.035 and PMC identifier 9085443.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Just over 1 year following rollout of the first vaccines for coronavirus disease 2019, 572 million doses have been administered in the United States. Compared with the number of vaccines administered, adverse effects such as anaphylaxis have been rare, and seemingly, the more serious the effect, the rarer the occurrence. Despite these adverse effects, there are few, if any, true contraindications to coronavirus disease 2019 vaccination and most individuals recover without further sequelae. This review provides guidance for the allergist/immunologist regarding appropriate next steps based on patient's known allergy history or adverse reaction after receipt of coronavirus disease 2019 vaccine to assist in safe global immunization.
Medical subject headings
- COVID-19
- COVID-19 Vaccines